The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Popova E.V.

Kafedra nervnykh bolezneĭ fakul'teta poslevuzovskogo professional'nogo obrazovaniia vracheĭ Moskovskoĭ meditsinskoĭ akademii im. I.M. Sechenova

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

Orlova E.V.

Dimethylfumarate in the treatment of relapsing-remitting multiple sclerosis

Authors:

Popova E.V., Boĭko A.N., Orlova E.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(10‑2): 68‑72

DOI: 10.17116/jnevro201611610268-72

Read: 1994 times

Download PDF (RU)
Contact the author
Table of contents

DIMETHYLFUMARATE IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
DIMETHYLFUMARATE IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS

To cite this article:

Popova EV, Boĭko AN, Orlova EV. Dimethylfumarate in the treatment of relapsing-remitting multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(10‑2):68‑72. (In Russ.)
https://doi.org/10.17116/jnevro201611610268-72

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Stress and sleep: Neurobiological aspe­cts and modern options of inso­mnia therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):14-21
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Combined treatment of patients with acute muscular tonic syndrome with dorsopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):70-77
Characteristics, treatment features and in-hospital mortality of patients with myocardial infa­rction over 75 years old in Russia acco­rding to the REGION-IM regi­stry. Russian Cardiology Bulletin. 2025;(1):22-38
Pharmacological treatment and prevention of ischemia-reperfusion syndrome in percutaneous coro­nary inte­rvention. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):191-200
Influence of griseofulvin on inte­stinal microbiota in the treatment of microsporia in rural children. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):185-190
A clinical case of X-linked adre­noleukodystrophy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):102-107
Postoperative peri­tonitis: epidemiology, diagnosis, surgical treatment and prognosis. Piro­gov Russian Journal of Surgery. 2025;(6):104-111
Arti­ficial inte­lligence capa­bilities in multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):14-21
Early diagnosis and effe­ctive therapy of diabetic poly­neuropathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):62-68
Abstract:

This review includes results of experimental and clinical studies of dimethyl fumarate, a new oral drug for pathogenetic treatment of multiple sclerosis (MS). The mechanism of action, data from clinical trials, including MRI-results, related to tolerability and safety of the drug are reviewed. The risk management plan for possible adverse events and a place of dimethyl fumarate in the current pathogenetic treatment of MS are discussed.

Keywords:

multiple sclerosis
treatment
dimethyl fumarate

Authors:

Popova E.V.

Kafedra nervnykh bolezneĭ fakul'teta poslevuzovskogo professional'nogo obrazovaniia vracheĭ Moskovskoĭ meditsinskoĭ akademii im. I.M. Sechenova

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

Orlova E.V.

Close metadata

References:

  1. Mrowietz, Christophers, Altmeyer For The German Fumaric Aci. Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. British Journal of Dermatology. 1999;141(3):424-429. doi: 10.1046/j.1365-2133.1999.03034.x
  2. Hoefnagel J, Thio H, Willemze R, Bouwes Bavinck J. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol. 2003;149(2):363-369. doi: 10.1046/j.1365-2133.2003.05433.x
  3. Reich K, Thaci D, Mrowietz U, Kamps A, Neureither M, Luger T. Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis â A retrospective study (FUTURE). Journal der Deutschen Dermatologischen Gesellschaft. 2009;7(7):603-610. doi: 10.1111/j.1610-0387.2009.07120.x
  4. Schilling S, Goelz S, Linker R, Luehder F, Gold R. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clinical and Experimental Immunology. 2006;145(1):101-107. doi: 10.1111/j.1365-2249.2006.03094.x
  5. Moharregh-Khiabani D, Linker R, Gold R, Stangel M. Fumaric Acid and its Esters: An Emerging Treatment for Multiple Sclerosis. Current Neuropharmacology. 2009;7(1):60-64. doi: 10.2174/157015909787602788
  6. Litjens N, Burggraaf J, van Strijen E et al. Pharmacokinetics of oral fumarates in healthy subjects.British Journal of Clinical Pharmacology. 2004;58(4):429-432. doi: 10.1111/j.1365-2125.2004.02145.x
  7. Dubey D, Kieseier B, Hartung H et al. Dimethyl fumarate in relapsing — remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety. Expert Review of Neurotherapeutics. 2015;15(4):339-346. doi: 10.1586/14737175.2015.1025755
  8. Phillips J, Selmaj K, Gold R et al. Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate. International Journal of MS Care. 2015;17(5):236-243. doi: 10.7224/1537-2073.2014-069
  9. Albrecht P, Bouchachia I, Goebels N et al. Effects of dimethyl fumarate on neuroprotection and immunomodulation. Journal of Neuroinflammation. 2012;9(1):163. doi: 10.1186/1742-2094-9-163
  10. Zoghi S, Amirghofran Z, Nikseresht A, Ashjazadeh N, Kamali-Sarvestani E, Rezaei N. Cytokine Secretion Pattern in Treatment of Lymphocytes of Multiple Sclerosis Patients with Fumaric Acid Esters. Immunological Investigations. 2011;40(6):581-596. doi: 10.3109/08820139.2011.569626
  11. Werdenberg D, Joshi R, Wolffram S, Merkle H, Langguth P. Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters. Biopharm Drug Dispos. 2003;24(6):259-273. doi: 10.1002/bdd.364
  12. Lin S, Lisi L, Dello Russo C et al. The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1. ASN NEURO. 2011;3(2):75-84. doi: 10.1042/an20100033
  13. Longbrake E, Ramsbottom M, Cantoni C, Ghezzi L, Cross A, Piccio L. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients. Multiple Sclerosis Journal. 2015. doi: 10.1177/1352458515608961
  14. Gold R, Kappos L, Arnold D et al. Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis. New England Journal of Medicine. 2012;367(12):1098-1107. doi: 10.1056/nejmoa1114287
  15. Fox R, Miller D, Phillips J et al. Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis. New England Journal of Medicine. 2012;367(12):1087-1097. doi: 10.1056/nejmoa1206328
  16. Spencer C, Crabtree-Hartman E, Lehmann-Horn K, Cree B, Zamvil S. Reduction of CD8+ T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. Neurology: Neuroimmunology & Neuroinflammation. 2015;2(3):76. doi: 10.1212/nxi.0000000000000076
  17. Berkovich RWeiner L. Effects of dimethyl fumarate on lymphocyte subsets. Multiple Sclerosis and Related Disorders. 2015;4(4):339-341. doi: 10.1016/j.msard.2015.06.002
  18. Scannevin R, Chollate S, Jung M et al. Fumarates Promote Cytoprotection of Central Nervous System Cells against Oxidative Stress via the Nuclear Factor (Erythroid-Derived 2)-Like 2 Pathway. Journal of Pharmacology and Experimental Therapeutics. 2012;341(1):274-284. doi: 10.1124/jpet.111.190132
  19. Chen H, Assmann J, Krenz A et al. Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE. Journal of Clinical Investigation. 2014;124(5):2188-2192. doi: 10.1172/jci72151
  20. Parodi B, Rossi S, Morando S et al. Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS. Acta Neuropathologica. 2015;130(2):279-295. doi: 10.1007/s00401-015-1422-3
  21. Linker R, Lee D, Ryan S et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain. 2011;134(3):678-692. doi: 10.1093/brain/awq386
  22. Hanson J, Gille A, Zwykiel S et al. Nicotinic acid- and monomethyl fumarate — induced flushing involves GPR109A expressed by keratinocytes and COX-2 — dependent prostanoid formation in mice. Journal of Clinical Investigation. 2010;120(8):2910-2919. doi: 10.1172/jci42273
  23. Schimrigk S, Brune N, Hellwig K et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol. 2006;13(6):604-610. doi: 10.1111/j.1468-1331.2006.01292.x
  24. MacManus D, Miller D, Kappos L et al. BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. Journal of Neurology. 2010;258(3):449-456. doi: 10.1007/s00415-010-5777-z
  25. O’Gorman J, Russell H, Li J, Phillips G, Kurukulasuriya N, Viglietta V. Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate. Clinical Therapeutics. 2015;37(7):1402-1419. doi: 10.1016/j.clinthera.2015.03.028
  26. Longbrake E, Naismith R, Parks B, Wu G, Cross A. Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance. Multiple Sclerosis Journal — Experimental, Translational and Clinical. 2015;1(0). doi: 10.1177/2055217315596994
  27. New EMA recommendations on Tecfidera. Reactions Weekly. 2015;1576(1):7. doi: 10.1007/s40278-015-10164-9
  28. Buttmann M, Stoll G. Case Reports of PML in Patients Treated for Psoriasis. New England Journal of Medicine. 2013;369(11):1080-1082. doi: 10.1056/nejmc1307680
  29. Ermis U, Weis J, Schulz J. PML in a Patient Treated with Fumaric Acid. New England Journal of Medicine. 2013;368(17):1657-1658. doi: 10.1056/nejmc1211805
  30. Van Oosten B, Killestein J, Barkhof F, Polman C, Wattjes M. PML in a Patient Treated with Dimethyl Fumarate from a Compounding Pharmacy. New England Journal of Medicine. 2013;368(17):1658-1659. doi: 10.1056/nejmc1215357
  31. Stoppe M, Thomä E, Liebert U et al. Cerebellar manifestation of PML under fumarate and after efalizumab treatment of psoriasis. Journal of Neurology. 2014;261(5):1021-1024. doi: 10.1007/s00415-014-7311-1
  32. Dammeier N, Schubert V, Hauser T, Bornemann A, Bischof F. Case report of a patient with progressive multifocal leukoencephalopathy under treatment with dimethyl fumarate. BMC Neurology. 2015;15(1). doi: 10.1186/s12883-015-0363-8
  33. Nieuwkamp D, Murk J, Cremers C et al. PML in a Patient without Severe Lymphocytopenia Receiving Dimethyl Fumarate. New England Journal of Medicine. 2015;372(15):1474-1476. doi: 10.1056/nejmc1413724
  34. Rosenkranz T, Novas M, Terborg C. PML in a Patient with Lymphocytopenia Treated with Dimethyl Fumarate. New England Journal of Medicine. 2015;372(15):1476-1478. doi: 10.1056/nejmc1415408
  35. Inc. M. Real-world clinical outcomes in relapsing-remitting multiple sclerosis patients who switch from natalizumab to delayed-release dimethyl fumarate: a multicenter, retrospective, observational study (STRATEGY). Onlinelibraryectrims-congresseu. 2016. Accessed April 24, 2016. Available at: http://onlinelibrary.ectrims-congress.eu/ectrims/2015/31st/115559/ stanley.cohan.real-world.clinical.outcomes.in.relapsing-remitting. multiple.html?fm3
  36. Calkwood J, Vollmer T, Fox R et al. Safety and Tolerability of Delayed-Release Dimethyl Fumarate (DMF) When Administered in Combination with Interferon Beta or Glatiramer Acetate in Relapsing-Remitting MS. International Journal of MS Care. 2015. doi: 10.7224/1537-2073.2015-020
  37. Wallbrecht K, Drick N, Hund A, Schön M. Downregulation of endothelial adhesion molecules by dimethylfumarate, but not monomethylfumarate, and impairment of dynamic lymphocyte-endothelial cell interactions. Experimental Dermatology. 2011;20(12):980-985. doi: 10.1111/j.1600-0625.2011.01376.x
  38. Rubant S, Ludwig R, Diehl S et al. Dimethylfumarate Reduces Leukocyte Rolling in Vivo through Modulation of Adhesion Molecule Expression. Journal of Investigative Dermatology. 2008;128(2):326-331. doi: 10.1038/sj.jid.5700996
  39. Utz K, Hoog J, Wentrup A et al. Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis. Therapeutic Advances in Neurological Disorders. 2014;7(6):263-275. doi: 10.1177/1756285614555335
  40. Inc. M. Longer-term follow-up of the efficacy of delayed-release dimethyl fumarate in newly diagnosed patients with RRMS: an integrated analysis of DEFINE, CONFIRM, and ENDORSE. Onlinelibraryectrims-congresseu. 2016. Accessed April 24, 2016. Available at: http://onlinelibrary.ectrims-congress.eu/ectrims/2015/31st/115560/
  41. Viglietta V, Miller D, Bar-Or A et al. Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials. Annals of Clinical and Translational Neurology. 2014;2(2):103-118. doi: 10.1002/acn3.148
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.